title: Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI).
abstract: OBJECTIVE
  To identify factors in patients with type 2 diabetes and A1C >7.0% associated with attainment of A1C ≤ 7.0%.
  
  
  METHODS
  We used a prospective registry of 5,280 Canadian patients in primary care settings enrolled in a 12-month glycemic pharmacotherapy optimization strategy based on national guidelines.
  
  
  RESULTS
  At close out, median A1C was 7.1% (vs. 7.8% at baseline) with 48% of subjects achieving A1C ≤ 7.0% (P < 0.0001). Older patients of Asian or black origin, those with longer diabetes duration, those with lower baseline A1C, BMI, LDL cholesterol, and blood pressure, and those on angiotensin receptor blockers and a lower number of antihyperglycemic agents, were more likely to achieve A1C ≤ 7.0% at some point during the study (all P < 0.0235). Access to private versus public drug coverage did not impact glycemic target realization.
  
  
  CONCLUSIONS
  Patient demography, cardiometabolic health, and ongoing pharmacotherapy, but not access to private drug insurance coverage, contribute to the care gap in type 2 diabetes.
authors.affiliation: Division of Cardiac Surgery, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
authors.forename: Hwee
authors.initials: H
authors.lastname: Teoh
authors.forename: Manoela F B
authors.initials: MF
authors.lastname: Braga
authors.forename: Amparo
authors.initials: A
authors.lastname: Casanova
authors.forename: Denis
authors.initials: D
authors.lastname: Drouin
authors.forename: Shaun G
authors.initials: SG
authors.lastname: Goodman
authors.forename: Stewart B
authors.initials: SB
authors.lastname: Harris
authors.forename: Anatoly
authors.initials: A
authors.lastname: Langer
authors.forename: Mary K
authors.initials: MK
authors.lastname: Tan
authors.forename: Ehud
authors.initials: E
authors.lastname: Ur
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Yan
authors.forename: Bernard
authors.initials: B
authors.lastname: Zinman
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Leiter
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000208:ethnology / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D057911:Angiotensin Receptor Antagonists; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents
references.citation: Diabetes Educ. 2005 Jul-Aug;31(4):564-71
references.pmid: 16100332
references.citation: Can J Cardiol. 2010 Jun-Jul;26(6):297-302
references.pmid: 20548975
references.citation: N Engl J Med. 2005 Dec 22;353(25):2643-53
references.pmid: 16371630
references.citation: Biometrics. 2001 Mar;57(1):120-5
references.pmid: 11252586
references.citation: N Engl J Med. 2008 Jun 12;358(24):2545-59
references.pmid: 18539917
references.citation: Diabetes Care. 2005 Mar;28(3):600-6
references.pmid: 15735195
references.citation: Can J Diabetes. 2013 Apr;37 Suppl 1:S1-3
references.pmid: 24070926
references.citation: N Engl J Med. 2009 Jan 8;360(2):129-39
references.pmid: 19092145
references.citation: BMJ. 2000 Aug 12;321(7258):405-12
references.pmid: 10938048
references.citation: Diabetes Care. 2006 Mar;29(3):531-7
references.pmid: 16505501
references.citation: Diabetologia. 2009 Nov;52(11):2288-98
references.pmid: 19655124
references.citation: N Engl J Med. 2008 Jun 12;358(24):2560-72
references.pmid: 18539916